lansoprazole has been researched along with s 1743 in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (50.00) | 29.6817 |
| 2010's | 42 (40.38) | 24.3611 |
| 2020's | 10 (9.62) | 2.80 |
| Authors | Studies |
|---|---|
| Kromer, W | 1 |
| Castell, DO; Johnson, DA; Kahrilas, PJ; Levine, JG; Richter, JE; Skammer, W; Vakil, NB; Zuckerman, S | 1 |
| Katz, PO | 1 |
| Tahboub, RM; Vanderhoff, BT | 1 |
| Boon, YH; Cheng, CS; Chian, LC; Chiu, TC; Kaushik, S; Vu, C | 1 |
| Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K | 2 |
| Vakil, N | 1 |
| He, LH; Yan, XM; Yin, Y; You, YH; Zhang, JZ | 1 |
| Hellström, PM; Vitols, S | 1 |
| Edwards, SJ; Green, JR; Raghunath, AS | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Chen, Y; Katz, PO; Miner, P; Sostek, M | 1 |
| Junghard, O; Nilsson-Pieschl, C; Nyman, L; Röhss, K; Wilder-Smith, CH | 1 |
| Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I | 1 |
| Aeed, H; Avni, Y; Boaz, M; Levine, A; Moss, SF; Niv, Y; Shabat-Sehayek, V; Shevah, O; Shirin, H | 1 |
| Ahlström, M; Andersson, TB; Li, XQ; Weidolf, L | 1 |
| Levine, D; Traxler, BM; Vakil, NB | 1 |
| Lind, T; Röhss, K; Wilder-Smith, C | 1 |
| Anderson, M; Chapman, R; Duggan, S; McKeith, D; Rosen, JP; Shepherd, A; Tsai, HH; Vearer, D | 1 |
| Freston, JW | 1 |
| Fennerty, MB; Hwang, C; Johanson, JF; Sostek, M | 1 |
| Baldi, F | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bagel-Boithias, S; Chopineau, J; Messaouik, D; Sautou-Miranda, V | 1 |
| Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF | 1 |
| Brooks, W; Doviak, M; Hornbuckle, K; Johnson, DA; Ryan, M; Stacy, T; Willis, J; Wootton, T | 1 |
| Brown, RE; Remák, E; Robinson, A; Yuen, C | 1 |
| De Micheli, E; Frazzoni, M; Manno, M; Savarino, V | 1 |
| Calvet, X; Gomollón, F | 1 |
| Fass, R; Sontag, SJ; Sostek, M; Traxler, B | 1 |
| Baker, DE | 1 |
| Goldstein, JL; Liu, S; Miner, PB; Schlesinger, PK; Silberg, DG | 1 |
| Devault, KR; Johanson, JF; Johnson, DA; Liu, S; Sostek, MB | 1 |
| Dohmen, W; Fuchs, W | 1 |
| Clark, DW; Strandell, J | 1 |
| Edwards, SJ; Lind, T; Lundell, L | 1 |
| Klotz, U | 1 |
| Bakshi, A; Bungay, K; Devlin, JW; Olsen, KM | 1 |
| Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS | 1 |
| Lind, T; Lundin, C; Nauclér, E; Nilsson-Pieschl, C; Röhss, K; Wilder-Smith, C | 1 |
| Molnar, B; Mullner, K; Tulassay, Z | 1 |
| Miner, PB; Monyak, JT; Pisegna, JR; Sostek, MB | 1 |
| Andersson, T; Weidolf, L | 1 |
| Charlemagne, A; Fagnani, F; Le Jeunne, P; Mouly, S | 1 |
| Leufkens, HG; Martini, N; Sagliocca, L; Tafuri, G; Traversa, G; Trotta, F | 1 |
| Farrell, CP; Gabello, M; Martin, AP; Morgan, M; Mullin, JM; Murray, LJ; Rudolph, DS; Underwood, JC; Valenzano, MC | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| Huang, Z; Shi, R; Wang, J; Wang, X; Xu, Z; Yang, Y; Zhang, G; Zhao, F | 1 |
| Zheng, RN | 1 |
| Barker, PN; Silberg, DG; Spechler, SJ | 1 |
| DAS, R; Edwards, SJ; Lind, T; Lundell, L | 1 |
| Hunt, RH; Padol, S; Yaghoobi, M; Yuan, Y | 1 |
| Fegely, K; Missaghi, S; Rajabi-Siahboomi, AR; Young, C | 1 |
| Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J | 1 |
| Antonioli, L; Awwad, O; Basolo, F; Blandizzi, C; Colucci, R; Fornai, M; Fulceri, F; Natale, G; Tuccori, M; Ugolini, C | 1 |
| Illueca, M; Johnson, DA; Monyak, JT; Sharma, P | 1 |
| Buckley, DB; Kazmi, F; Ogilvie, BW; Paris, BL; Parkinson, A; Rostami-Hodjegan, A; Toren, P; Yerino, P | 1 |
| Htun, WW; Huang, Y; Ko, W; Kwan, J; Kwan, TW | 1 |
| Bhatt, DL; Brooks, JK; Frelinger, AL; Lee, RD; Michelson, AD; Mulford, DJ; Nigam, A; Nudurupati, S; Wu, J | 1 |
| Chang, SY; Chen, C; Chimalakonda, A; Hurley, J; Rodrigues, AD; Thorndike, D; Vuppugalla, R; Wagner, A; Yang, Z; Zvyaga, T | 1 |
| Lin, HJ; Soon, MS; Su, WW; Wu, SS; Yang, CW; Yen, HH | 1 |
| Chularojanamontri, L; Dhana, N; Jiamton, S; Jongjarearnprasert, K; Kulthanan, K; Manapajon, A; Suvanasuthi, S | 1 |
| Banahan, BF; Bentley, JP; Datar, MV; Mahabaleshwarkar, RK; Null, KD; Strum, MW; Yang, Y | 1 |
| Cooke, JP; Erlanson, DA; Ghebremariam, YT; Lee, JC; Leiper, J; LePendu, P; Shah, NH; Slaviero, A | 1 |
| Metz, DC; Shah, P; Singh, MH; Yang, YX | 1 |
| Hatlebakk, JG; Jonasson, C; Tvete, IF | 1 |
| Furuta, T; Ichikawa, H; Iwaizumi, M; Miyajima, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Yamada, T; Yamade, M | 1 |
| Angioli, R; Damiani, P; Improta, G; Petrella, C; Plotti, F; Scarpignato, C; Severini, C; Signore, F; Terranova, C | 1 |
| Kara, M; Kekilli, M; Kutlu, A; Sirkeci, O; Tanoglu, A | 1 |
| Andersson, T; Galbraith, H; Nagy, P; Niazi, M; Nylander, S; Ranjan, S; Wallentin, L | 1 |
| Egawa, S; Fukui, H; Ichiba, M; Iijima, H; Inoue, A; Ishihara, R; Kishida, O; Kobayashi, I; Komori, M; Nishida, T; Ogawa, H; Oshita, M; Takeda, A; Takehara, T; Tanimura, H; Tsuji, S; Tsujii, M; Tsutsui, S; Uenoyama, N; Yasunaga, Y; Yoshio, T; Yura, M; Zushi, S | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Bilker, WB; Brensinger, CM; Flockhart, DA; Freeman, CP; Hennessy, S; Kasner, SE; Kimmel, SE; Leonard, CE | 1 |
| Armstrong, D; Baldycheva, I; Labenz, J; Leodolter, A | 1 |
| Liu, F; Shokrollahi, H | 1 |
| Akers, KS; Boyd, NK; Niece, KL | 1 |
| Abbas, MG; Akter, N; Akter, S; Bhuiyan, MA; Hassan, MR; Shahriar, M | 1 |
| Niv, Y | 1 |
| Alkeraye, S; Baclet, Y; Delaporte, E | 1 |
| Christensen, RD; Haastrup, PF; Hansen, JM; Jarbøl, DE; Paulsen, MS; Søndergaard, J | 1 |
| Chen, MH; Chu, CJ; Hou, MC; Huang, YH; Lee, FY; Lin, HC; Lu, CL; Su, TP; Tsai, CF; Wang, YP | 1 |
| Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö | 1 |
| Li, MJ; Li, Q; Liu, LQ; Sun, M | 1 |
| Al-Huniti, N; Bui, KH; Cheung, SYA; Johnson, TN; Li, J; Xu, H; Zhou, D; Zhou, W | 1 |
| Chen, D; Fei, G; Lu, B; Wang, B; Wang, J; Wang, X; Wu, B; Zhang, L; Zou, D; Zou, X | 1 |
| Hatakeyama, S; Hosogoe, S; Imanishi, K; Ohyama, C; Okamoto, T; Saitoh, F; Suzuki, T; Takashima, T; Tanaka, Y | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Calissendorff, J; Falhammar, H; Lindh, JD; Mannheimer, B; Nathanson, D; Skov, J | 1 |
| Shahbazi, S; Vahdat Shariatpanahi, Z | 1 |
| Higashi, T; Inoue, R; Mitsutake, T; Morinaga, Y; Nii, K | 1 |
| Kan, LD; Li, LC; Wu, CY; Ying, J; Yu, ZW | 1 |
| Feldon, SE; Hammond, CL; Phipps, RP; Roztocil, E; Woeller, CF | 1 |
| Karimova, MM; Makarenko, OV; Masheiko, AM; Onul, NM | 1 |
| Abed, MN; Alassaf, FA; Alfahad, M; Jasim, MHM; Qazzaz, ME | 1 |
| Bögeholz, N; Burde, S; Eckardt, L; Ellermann, C; Fehr, M; Frommeyer, G; Leitz, P; Willy, K; Wolfes, J | 1 |
| Chen, G; Li, XM; Mei, D; Ning, LJ; Qin, Y; Zhao, B | 1 |
| Hongo, M; Hunt, RH; Lazarescu, A; Lottrup, C; Scarpignato, C; Stein, E; Wu, JCY | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Chan, AT; Choi, HK; Lei, G; Lu, N; Misra, D; Neogi, T; Wei, J; Zeng, C; Zhang, Y | 1 |
| Beard, S; Binder, NK; de Alwis, N; Hannan, NJ; Kaitu'u-Lino, TJ; Pritchard, N; Tong, S | 1 |
| Deguchi, H; Fernandez, J; Igarashi, A; Ishii, M; Kawai, T; Suzuki, M; Tsujita, K | 1 |
| Lespessailles, E; Toumi, H | 1 |
| Bai, YM; Chang, YT; Chen, MH; Chen, TJ; Chiou, SH; Li, CY; Tsai, SJ; Wang, WT | 1 |
23 review(s) available for lansoprazole and s 1743
| Article | Year |
|---|---|
Gastroesophageal reflux disease: new treatments.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Humans; Lansoprazole; Length of Stay; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Recurrence; Survival Analysis; Treatment Outcome | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esomeprazole; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2003 |
A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Proton Pump Inhibitors | 2003 |
Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Esomeprazole; Evaluation Studies as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Prognosis; Proton Pump Inhibitors; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Proton Pump Inhibitors; Tablets; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
What is potent acid inhibition, and how can it be achieved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Esomeprazole; Gastric Acid; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2005 |
Intravenous proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Drug Interactions; Esomeprazole; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Pantoprazole; Proton Pump Inhibitors; Stomach; Sulfoxides | 2006 |
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Muscular Diseases; Myositis; Omeprazole; Pantoprazole; Polymyositis; Proton Pump Inhibitors; Rabeprazole; Rhabdomyolysis | 2006 |
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Enzyme Inhibitors; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2006 |
Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors | 2006 |
[Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2007 |
Stereoselective disposition of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Esomeprazole; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Stereoisomerism | 2008 |
Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Controlled Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Heterozygote; Homozygote; Humans; Lansoprazole; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2008 |
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Randomized Controlled Trials as Topic; Registries; Wound Healing | 2010 |
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Network Meta-Analysis; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides | 2020 |
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoporotic Fractures; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; United States | 2022 |
32 trial(s) available for lansoprazole and s 1743
| Article | Year |
|---|---|
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Digestive System; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Severity of Illness Index; Wound Healing | 2002 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Recurrence; Survival Analysis; Treatment Outcome | 2003 |
Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole; Proton Pump Inhibitors; Treatment Outcome | 2003 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Humans; Lansoprazole | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-Square Distribution; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2003 |
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Rabeprazole | 2003 |
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Esomeprazole; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Urea | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Rabeprazole; Sulfoxides; Treatment Outcome | 2004 |
Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Middle Aged; Patient Satisfaction; Single-Blind Method; Treatment Outcome | 2004 |
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Wound Healing | 2005 |
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Cross-Over Studies; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Treatment Outcome | 2005 |
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Esomeprazole; Esophagitis, Peptic; Esophagus; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Manometry; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2006 |
Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomeprazole; Female; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors | 2006 |
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lansoprazole; Least-Squares Analysis; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2006 |
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Digestive System; Esomeprazole; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Treatment Outcome | 2006 |
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Esomeprazole; Esophagitis, Peptic; Family Practice; Female; Germany; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Recurrence | 2005 |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2007 |
Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Gastric Acid; Gastric Acidity Determination; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2007 |
Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Injections, Intravenous; Lansoprazole; Male; Middle Aged | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Patient Selection | 2009 |
Clinical trial: intragastric acid control in patients who have Barrett's oesophagus--comparison of once- and twice-daily regimens of esomeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Barrett Esophagus; Cross-Over Studies; Esomeprazole; Esophageal pH Monitoring; Female; Humans; Lansoprazole; Male; Middle Aged; Treatment Outcome | 2009 |
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Drug Therapy, Combination; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Hispanic or Latino; Humans; Lansoprazole; Male; Middle Aged; Pantoprazole; Patient Compliance; Treatment Outcome; United States; Young Adult | 2010 |
A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Blood Coagulation; Blood Platelets; Clopidogrel; Confidence Intervals; Cross-Over Studies; Dexlansoprazole; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Reference Values; Ticlopidine; Young Adult | 2012 |
Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Aged; Anti-Ulcer Agents; Blood Transfusion; Endoscopy; Esomeprazole; Female; Humans; Lansoprazole; Length of Stay; Male; Middle Aged; Peptic Ulcer; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Secondary Prevention; Treatment Outcome | 2012 |
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Topics: Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Esomeprazole; Female; Gastric Acid; Genotype; Humans; Hydrogen-Ion Concentration; Japan; Lansoprazole; Male; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2013 |
Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Aspirin; Clopidogrel; Cross-Over Studies; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Healthy Volunteers; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Platelet Aggregation; Proton Pump Inhibitors; Ticlopidine; Young Adult | 2014 |
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Japan; Lansoprazole; Male; Middle Aged; Prospective Studies; Time Factors; Young Adult | 2014 |
Management of reflux esophagitis: does the choice of proton pump inhibitor matter?
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Esophagitis, Peptic; Follow-Up Studies; Humans; Lansoprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2015 |
Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cognition; Esomeprazole; Female; Humans; Lansoprazole; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Software; Young Adult | 2015 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double-Blind Method; Esomeprazole; Female; Gastric Acid; Gastroesophageal Reflux; Genotype; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2016 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Patient Compliance; Tinidazole; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
50 other study(ies) available for lansoprazole and s 1743
| Article | Year |
|---|---|
Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Half-Life; Humans; Hydrogen-Ion Concentration; Lansoprazole; Omeprazole; Pantoprazole; Parietal Cells, Gastric; Prodrugs; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2001 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Sulfoxides | 2002 |
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Prospective Studies; Treatment Outcome | 2002 |
[In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esomeprazole; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Proton Pump Inhibitors; Rabeprazole | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Models, Economic; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2004 |
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Humans; Lansoprazole; Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Sulfoxides | 2004 |
Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Serologic Tests | 2004 |
Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Beverages; Esomeprazole; Intubation, Gastrointestinal; Lansoprazole; Malus; Omeprazole; Particle Size; Polyurethanes; Proton Pump Inhibitors; Rheology; Silicones; Solvents; Water | 2005 |
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Administration Schedule; Enzyme Inhibitors; Esomeprazole; Female; Fiber Optic Technology; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Hypopharynx; Lansoprazole; Laryngoscopy; Male; Manometry; Middle Aged; Omeprazole; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; United Kingdom | 2005 |
An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esomeprazole; Female; Humans; Infusions, Parenteral; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Satisfaction; Proton Pump Inhibitors; Proton Pumps | 2006 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomeprazole; Family Practice; Female; France; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pumps; Rabeprazole | 2008 |
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Utilization Review; Esomeprazole; European Union; Gastroesophageal Reflux; Government Agencies; Humans; Isomerism; Lansoprazole; Multicenter Studies as Topic; Omeprazole; Pediatrics; Proton Pump Inhibitors; United States; United States Food and Drug Administration | 2009 |
Transmucosal gastric leak induced by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Epithelium; Esomeprazole; Gastric Mucosa; Hydrogen-Ion Concentration; In Vitro Techniques; Lansoprazole; Male; Omeprazole; Permeability; Proton Pump Inhibitors; Rats; Rats, Sprague-Dawley | 2009 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Stability; Drug Storage; Esomeprazole; Excipients; Kinetics; Lansoprazole; Proton Pump Inhibitors; Solubility; Tablets, Enteric-Coated | 2010 |
Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Esomeprazole; Famotidine; Gastric Acid; Gastric Mucosa; Histamine H2 Antagonists; Immunohistochemistry; Indomethacin; Ki-67 Antigen; Lansoprazole; Male; Malondialdehyde; Proliferating Cell Nuclear Antigen; Proton Pump Inhibitors; Rats; Rats, Wistar; Stomach Ulcer; Time Factors; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Esophagitis, Peptic; Faith Healing; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Logistic Models; Los Angeles; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Racial Groups; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Inhibitory Concentration 50; Lansoprazole; Microsomes; Microsomes, Liver; Omeprazole; Pantoprazole; Protein Binding; Proton Pump Inhibitors; Recombinant Proteins; Ticlopidine | 2011 |
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian; Asian People; Blood Platelets; China; Clopidogrel; Drug Resistance; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; New York City; Omeprazole; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Stents; Thrombosis; Ticlopidine; Time Factors | 2011 |
Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cells, Cultured; Computer Simulation; Cytochrome P-450 CYP2C19; Dealkylation; Dexlansoprazole; Diazepam; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Esomeprazole; Hepatocytes; Humans; Kinetics; Lansoprazole; Liver; Microsomes, Liver; Models, Biological; NADP; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Recombinant Proteins; Substrate Specificity | 2012 |
Cutaneous reactions to proton pump inhibitors: a case-control study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Case-Control Studies; Chi-Square Distribution; Drug Eruptions; Esomeprazole; Exanthema; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Prevalence; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Statistics, Nonparametric; Stevens-Johnson Syndrome; Thailand; Urticaria; Young Adult | 2012 |
Risk of adverse cardiovascular outcomes and all-cause mortality associated with concomitant use of clopidogrel and proton pump inhibitors in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Interactions; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Myocardial Infarction; Omeprazole; Pantoprazole; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Rabeprazole; Risk; Stroke; Ticlopidine | 2013 |
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Esomeprazole; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Proton Pump Inhibitors; Risk Factors; Vasodilation | 2013 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Female; Gastric Acid; Gastric Mucosa; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rabeprazole; Secretin; Sensitivity and Specificity; Stomach; Young Adult; Zollinger-Ellison Syndrome | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; Health Policy; Humans; Insurance, Health, Reimbursement; Lansoprazole; Norway; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2013 |
Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Apamin; Calcium; Dinoprostone; Esomeprazole; Female; Humans; In Vitro Techniques; Indomethacin; Lansoprazole; Muscle Contraction; Myometrium; NG-Nitroarginine Methyl Ester; Omeprazole; Oxytocin; Pantoprazole; Peptides; Potassium Chloride; Pregnancy; Proton Pump Inhibitors; Rabeprazole; Tocolytic Agents | 2014 |
Esomeprazole: a safe alternative to lansoprazole allergy?
Topics: Adult; Drug Hypersensitivity; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Skin Tests | 2014 |
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Brain Ischemia; Clopidogrel; Data Interpretation, Statistical; Drug Therapy, Combination; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proportional Hazards Models; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Risk; Stroke; Ticlopidine | 2015 |
In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Topics: Age Factors; Bicarbonates; Buffers; Chemistry, Pharmaceutical; Esomeprazole; Geriatrics; Humans; Hydrogen-Ion Concentration; Kinetics; Lansoprazole; Omeprazole; Particle Size; Pediatrics; Phosphates; Proton Pump Inhibitors; Sodium Chloride; Solubility; Tablets, Enteric-Coated; Technology, Pharmaceutical | 2015 |
In vitro study of the variable effects of proton pump inhibitors on voriconazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antifungal Agents; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Interactions; Esomeprazole; Humans; Lansoprazole; Microsomes, Liver; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Voriconazole | 2015 |
Sticky Palms Following Use of Proton-Pump Inhibitors.
Topics: Administration, Oral; Adult; Drug Eruptions; Esomeprazole; Female; Gastroesophageal Reflux; Hand Dermatoses; Humans; Lansoprazole; Male; Proton Pump Inhibitors; Stomach Ulcer | 2016 |
Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2016 |
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administrative Claims, Healthcare; Adult; Aged; Case-Control Studies; Esomeprazole; Female; Hepatic Encephalopathy; Humans; Incidence; Insurance, Health; Lansoprazole; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Taiwan | 2017 |
Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Topics: Acetates; Analgesics, Opioid; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Bronchodilator Agents; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Esomeprazole; Histamine H1 Antagonists, Non-Sedating; Humans; Infant; Infant, Newborn; Itraconazole; Lansoprazole; Loratadine; Models, Biological; Ondansetron; Pharmaceutical Preparations; Pharmacokinetics; Proton Pump Inhibitors; Quinolines; Serotonin Antagonists; Sufentanil; Sulfides; Theophylline; Tramadol | 2018 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Outpatients; Pantoprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Time Factors; Treatment Outcome; Young Adult | 2018 |
Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Topics: Aged; Aorta, Abdominal; Computed Tomography Angiography; Disease Progression; Esomeprazole; Female; Humans; Kidney Failure, Chronic; Lansoprazole; Logistic Models; Magnesium; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Renal Dialysis; Retrospective Studies; Vascular Calcification | 2018 |
Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Hyponatremia; Lansoprazole; Logistic Models; Male; Middle Aged; Multivariate Analysis; Omeprazole; Pantoprazole; Population; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sweden; Young Adult | 2019 |
Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dual Anti-Platelet Therapy; Esomeprazole; Female; Humans; Lansoprazole; Male; Middle Aged; Neurosurgical Procedures; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Retrospective Studies; Thromboembolism | 2019 |
The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; China; Comorbidity; Esomeprazole; Female; Health Care Surveys; Hospitals; Humans; Inappropriate Prescribing; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2019 |
Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor.
Topics: Actins; Calcium-Binding Proteins; Calponins; Cell Differentiation; Cells, Cultured; Cicatrix; Collagen; Esomeprazole; Fibroblasts; Graves Ophthalmopathy; HEK293 Cells; Humans; Lansoprazole; Microfilament Proteins; Myofibroblasts; Proton Pump Inhibitors; Receptors, Aryl Hydrocarbon; Transforming Growth Factor beta; Wnt Signaling Pathway | 2019 |
Qualimetric analysis of proton pump inhibitors in Ukraine.
Topics: Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Quality Control; Rabeprazole; Ukraine | 2019 |
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.
Topics: Antioxidants; Ascorbic Acid; Biphenyl Compounds; Esomeprazole; Free Radicals; In Vitro Techniques; Inhibitory Concentration 50; Lansoprazole; Omeprazole; Pantoprazole; Picrates; Proton Pump Inhibitors; Rabeprazole; Spectrophotometry | 2020 |
Concomitant Treatment with Proton Pump Inhibitors and Cephalosporins Does Not Enhance QT-Associated Proarrhythmia in Isolated Rabbit Hearts.
Topics: Action Potentials; Animals; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Ceftriaxone; Drug Interactions; Esomeprazole; Female; Heart Conduction System; Heart Rate; Isolated Heart Preparation; Lansoprazole; Proton Pump Inhibitors; Rabbits; Refractory Period, Electrophysiological; Risk Assessment; Time Factors | 2020 |
Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Topics: Acute Kidney Injury; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Esomeprazole; Female; Hospitalization; Humans; Lansoprazole; Male; Middle Aged; Product Surveillance, Postmarketing; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
Proton pump inhibitor therapy and risk of knee replacement surgery: a general population-based cohort study.
Topics: Cohort Studies; Esomeprazole; Humans; Lansoprazole; Omeprazole; Osteoarthritis, Knee; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2022 |
Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors.
Topics: Antioxidants; Esomeprazole; Female; Humans; Hypoxia; Infant, Newborn; Lansoprazole; Microfilament Proteins; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Prostaglandins F; Proton Pump Inhibitors; rho GTP-Binding Proteins; Vascular Endothelial Growth Factor Receptor-1 | 2022 |
Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Esomeprazole; Gastrointestinal Hemorrhage; Humans; Japan; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Secondary Prevention | 2023 |
Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study.
Topics: Asthma; Case-Control Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Proton Pump Inhibitors | 2023 |